CJC-1295 vs GHRP-6: Head-to-Head Comparison
CJC-1295 (GHRH pathway) and GHRP-6 (ghrelin pathway) target different receptors for GH release. They are synergistic when combined. CJC-1295 provides sustained GH elevation while GHRP-6 triggers strong pulses and significant appetite stimulation.
Side-by-Side Comparison
| Dimension | CJC-1295 | GHRP-6 |
|---|---|---|
| Evidence Level | Phase II trials | Extensive preclinical and clinical data |
| FDA Status | Not approved | Not approved |
| Mechanism | GHRH receptor agonist | Ghrelin receptor agonist (strong ghrelin mimetic) |
| Appetite Effects | No significant appetite change | Intense hunger stimulation |
| Side Effects | Water retention, injection site reactions | Intense hunger, cortisol/prolactin rise, dizziness |
| Dosing Convenience | 1-2x weekly (DAC version) | 2-3x daily |
| Cost | Moderate | Low |
Peptide Overviews
CJC-1295
BHuman StudiesCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Available in two forms: with and without Drug Affinity Complex (DAC), which extends its half-life.
GHRP-6
BHuman StudiesGHRP-6 was one of the first synthetic GH secretagogues developed. It stimulates strong GH release but also significantly increases appetite through ghrelin receptor activation.
CJC-1295 vs GHRP-6: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.